Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

User has been using Nanoxidil for 4 months with some hair regrowth but is still experiencing shedding. They are considering starting Finasteride and are seeking advice on using both treatments together.

Using lice as an alternative to microneedling for hair loss treatment, with concerns about effectiveness and practicality. Some users humorously suggest genetically altering lice to produce beneficial compounds.

Microneedling is often combined with minoxidil for hair growth, but concerns about scalp damage, pain, and effectiveness deter some users. Alternatives like finasteride, dutasteride, tretinoin, and laser treatments are preferred by others.

The conversation discusses experimenting with microneedling for hair loss, specifically addressing non-responsiveness and the use of topical treatments like dutasteride, minoxidil, and tretinoin. The user seeks advice on effective frequency and depth combinations for better results.

The user experienced significant hair regrowth after starting oral minoxidil (2.5mg) and dutasteride (0.5mg) daily, and is considering resuming microneedling at home with a dermapen. They are concerned about potential risks of microneedling, such as scarring, and are seeking advice on needle length and frequency.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.

The conversation is about the proper frequency and needle length for microneedling to treat hair loss, with a user asking if they should use a 0.5 mm derma stamp daily and a 1.5 mm stamp once a week.

A 48-year-old who had been thinning since 25 and reached NW4-5 baldness saw no improvement with 1mg/day finasteride and 5% minoxidil twice a day after 8 months. After copying another person's routine, they now use 0.5mg finasteride, ketoconazole shampoo weekly, daily microneedling with 0.5mm and 1mm once a week, and apply minoxidil twice daily, resulting in baby hairs on their bald spot and temples after three months.

Microneedling should target depths of 0.5mm to 1.5mm for hair loss, with weekly sessions at 1mm recommended. Combining microneedling with Minoxidil is common for improved results.

The conversation discusses the steps for microneedling, specifically differentiating between medical needling (0.5-1.5mm) and cosmetic needling (0.3mm). It emphasizes the importance of cleaning and disinfecting before microneedling, regardless of needle length.

Daily microneedling at 0.25mm before applying minoxidil is debated, with some suggesting weekly microneedling is safer and more effective. Concerns include potential skin damage and systemic absorption, while alternatives like tretinoin are considered safer for enhancing minoxidil absorption.

Microneedling, when combined with finasteride and topical minoxidil, can enhance hair regrowth for male pattern baldness, especially at the temples. Users report varying success with needle depths between 0.5mm and 1.5mm, with stamps preferred over rollers to minimize scalp damage.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

Microneedling is discussed as a method to improve hair growth, with users sharing their experiences and results using different needle depths and frequencies. Treatments mentioned include minoxidil, finasteride, rosemary oil, and saw palmetto supplements.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

The "crunching" sound during microneedling is likely the needles penetrating the scalp's outer layers, not cutting hair. Users suggest using a derma stamp instead of a roller to avoid potential hair damage.

The user has been using finasteride for 2 years, nizoral for 1.5 years, topical minoxidil for 1 year, and microneedling for 3 months to treat hair loss but hasn't seen improvement or regrowth, even experiencing shedding with new treatments. They are concerned about continued thinning despite the treatments.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

Microneedling for hair loss, with a user sharing a 2.5-year experience using a Dr. Pen M8 device. No issues were reported with weekly 1.25mm sessions.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.